FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Buy Rating On Shares Of Quest Diagnostics

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We keep our 12-month price target at $235. This is based on a forward P/E of 21.9x our 2026 EPS estimate, a premium to DGX's three-year forward average of 16.8x due to our view of strengthening sales and earnings growth, backed by higher health care utilization trends and some regulatory relief due to postponement of lab reimbursement cuts until at least 2027. We think lab testing providers remain a relatively well-positioned area within health care given lower policy risks, supportive testing demand, and attractive earnings growth potential. On a compounded annual basis from 2025-2028, we expect near 8% EPS growth, raising our 2026 EPS to $10.73 from $10.60 and 2027 EPS to $11.50 from $11.42. We also anticipate additional smaller M&A opportunities, along with healthy dividend increases (recent 7.5% boost; shares yield 1.7%) as cash flow generation remains supportive over the near term.

Related Articles

Asia

Corporate Travel Management Expects to Reverse Up to 118 Million Pounds Sterling of Revenue From Prior Results

Corporate Travel Management (ASX:CTD) now expects to reverse up to 118 million pounds sterling of revenue from fiscal year 2025 and prior years' results, up from a previously flagged amount of 77.6 million pounds sterling, according to a Wednesday filing with the Australian bourse.The development comes after the company hired KPMG to perform a forensic accounting review for certain years, with KPMG identifying areas of concern regarding the recognition of the UK group's concluded customer contracts and other revenue.The company said revenue of up to about 10 million pounds sterling may need to be reversed in the fiscal first-half results, depending on the outcome of commercial discussions with certain customers. The review confirmed that certain customers were charged above the contractual entitlement.Corporate Travel Management has made "significant changes" within its UK business, especially across financial controls and operational processes, it said, adding that the review has not identified any issues in other regions.The company aims to release audited fiscal year 2025 and reviewed fiscal first-half 2026 financial statements in the second quarter of the year.

$ASX:CTD
Asia

Northern Star Resources' Gold Sales Fall in March Quarter

Northern Star Resources (ASX:NST) said that the total gold sold for the March quarter was 380,807 ounces at an all-in sustaining cost (AISC) of AU$2,709 per ounce, according to a Wednesday Australian bourse filing.Total gold sold was 385,441 ounces at an AISC of AU$2,246 per ounce in the March 2025 quarter, an earlier filing showed.The company expects gold sales in fiscal 2026 to exceed 1.5 million ounces, with AISC projected between AU$2,600 and AU$2,800 per ounce.The company reported net cash of AU$320 million after paying a AU$347 million cash dividend, with total cash and bullion holdings amounting to AU$1.18 billion as of March 31.Northern Star Resources' shares shed around 2% in recent Wednesday trade.

$ASX:NST
Asia

Eisai, Merck's Phase 3 Kidney Cancer Drug Combo Trial Fails to Meet Survival Endpoints

Japanese pharmaceutical firm Eisai (TYO:4523) and U.S.-based Merck's experimental combination therapies failed to meet the dual primary endpoints of progression-free survival and overall survival in a Phase 3 trial.The trial was evaluating first-line treatment for advanced clear cell renal cell carcinoma, a form of kidney cancer that accounts for approximately 80% of all cases, according to a joint statement on Tuesday.The LITESPARK-012 study tested two regimens: Keytruda plus Lenvima plus Welireg, and MK-1308A (a co-formulation of Keytruda with an investigational antibody) plus Lenvima, against the established combination of Keytruda and Lenvima in 1,688 patients.An interim analysis revealed that neither experimental combination met the study's two primary goals of improving overall survival and progression-free survival compared with the standard treatment.

$TYO:4523